Copyright
©The Author(s) 2002.
World J Gastroenterol. Feb 15, 2002; 8(1): 13-20
Published online Feb 15, 2002. doi: 10.3748/wjg.v8.i1.13
Published online Feb 15, 2002. doi: 10.3748/wjg.v8.i1.13
Molecule | Effect on Intestinal Adaptation |
Glucagon-Like | Treatment of rats with a 75% mid small bowel resection with twice daily injections of 0.1ìg per gram of bodyweight for 21 d induced led to |
Peptide 2 | mucosal hyperplasia in the proximal jejunum but not in the terminal ileum and a significant increase in intestinal absorptive capacity[50]. |
Interleukin-11 | Treatment of rats with a 90% small bowel resectionwith twice daily injections of 125 mg·g-1ªª Il-11 significantly increasedvillus height and crypt |
cell mitotic rates[51]. | |
Keratinocyte Growth | Treatment of rats with a 75% small bowel resection with 3 mg·kg-1·d-1 of KGF enhanced intestinal adaptation as assessed by mucosal |
Factor (KGF) | cellularity, and biochemical activity in duodenal, jejunal and ileal segments[52]. |
Transforming factor-α | Treatment of mice with a 50% small bowel resection with intraperitoneal TGF-α enhanced intestinal adaptation[53]. |
Growth Hormone | Treatment of rats with a 75% small intestinal resection with 0.1 mg·kg-1·kg-1·2 d-1 d for 28 d enhanced ileal adaptation as assessed by ileal |
mucosal height. Treatment with growth hormone did not alter ileal mucosal DNA content or ileal mucosal IGF-1 content[54]. | |
Treatment of rats with an 80% jejunoileal resection with synthetic rat GH for up to 14 d did not enhance ileal adaptation[55]. | |
Treatment of an infant with only 25 cm of jejunum and 2 cm of ileum, with an ileocecal valve, with a 4-week course of 0.5 U/kg of GH | |
allowing wean ing from TPN[56]. | |
Ten patients with short bowel syndrome were treated with daily subcutaneous doses of recombinant human GH (rhGH) of 0.024 mg·kg-1·d-1 or a placebo for 8 wk in a crossover cli nical trial that included a wash-out period of at least 12 wk. Low-dose rhGH doubled serum levels | |
of IGF-1 and increased body weight and lean body mass; but there were no significant changes in absorptive capacity of water, energy, or protein[57]. | |
Insulin-like | Treatment of rats with 70% and 80% jejuno-ileal resection with IGF-1 or analogues significantly attenuated malabsorption of fat and |
Growth Factor-1 | increased weight of stomach and proximal small bowel[58]. |
Gastrostomy-fed rats underwent 80% jejuno-ileal resection followed by infusion of 2.4mg·kg-1·d-1 IGF-1 for 7 d. IGF-1 infusion led to a | |
modest increase in ileal but not jejunal growth[15]. | |
Treatment of TPN-fed rats for 7 d with IGF-1 after a 60% jejunoileal resection led to an increase in jejunal mass, enterocyte proliferation and | |
migration rates yet had minimal effect on colonic structure[59]. | |
Epidermal Growth | Treatment of rabbits with 2/3 proximal resection with oral EGF (40 µg·kg-1·d-1) for 5 d led to an increase in maltase specific activity and a 3 |
Factor (EGF) | -4 fold increase in glucose transport and phlorizin binding[60]. |
Treatment of rabbits with a 50%-60% small bowel resection with 0.3 µg·kg-1·h-1 for 7 d led to a foufold increase in mucosal dryweight at 3 | |
wk post-resection[61]. | |
Treatment of rats with a 75% small bowel resection with 6.25 µg·kg-1·h-1 of EGF increased mucosal thickness at 28 d post-resection[62]. | |
Neurotensin | Treatment of rats with a 75% small bowel resection with 600 µg·kg-1·d-1 led to an increase in the rate of mucosal proliferation[63]. |
- Citation: Platell CFE, Coster J, McCauley RD, Hall JC. The management of patients with the short bowel syndrome. World J Gastroenterol 2002; 8(1): 13-20
- URL: https://www.wjgnet.com/1007-9327/full/v8/i1/13.htm
- DOI: https://dx.doi.org/10.3748/wjg.v8.i1.13